[Advances in the application of gene therapy for Parkinson's disease with adeno-associated virus].

Abstract

Vectors used to carry foreign genes play an important role in gene therapy, among which, the adeno-associated virus (AAV) has many advantages, such as nonpathogenicity, low immunogenicity, stable and long-term expression and multiple-tissue-type infection, etc. These advantages have made AAV one of the most potential vectors in gene therapy, and widely used in many clinical researches, for example, Parkinson's disease. This paper introduces the biological characteristics of AAV and the latest research progress of AAV carrying neurotrophic factor, dopamine synthesis related enzymes and glutamic acid decarboxylase gene in the gene therapy of Parkinson's disease.

• Authors: Yang Chen, Ying-Hui Lü, Zhao-Fa Li
• Journal: Yao xue xue bao = Acta pharmaceutica Sinica (Yao Xue Xue Bao) Vol. 49 Issue 5 Pg. 576-81 (May 2014) ISSN: 0513-4870 [Print] China
• PMID: 25151724 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• CDNF protein, rat
• Glial Cell Line-Derived Neurotrophic Factor
• Nerve Growth Factors
• Neurturin
• Glutamate Decarboxylase
• Aromatic-L-Amino-Acid Decarboxylases

Topics

• Animals
• Aromatic-L-Amino-Acid Decarboxylases (genetics)
• Dependovirus (genetics)
• Gene Transfer Techniques
• Genetic Therapy
• Genetic Vectors
• Glial Cell Line-Derived Neurotrophic Factor (genetics)
• Glutamate Decarboxylase (genetics)
• Humans
• Nerve Growth Factors (genetics)
• Neurturin (genetics)
• Parkinson Disease (therapy)